MPN clinical Roadmap 2023

Introducing a new scientific initiative for clinicians in MPN from MD Education.

Each month, the co-chairs Raajit Rampal and Alessandro M. Vannucchi, and two guest speakers will dive deep into hot topics and have an open debate on current issues within the MPN field. Each expert presentation is followed by a question and answer session with one of the co-chairs and includes downloadable slides to enhance understanding.

Co-chair

Co-chair

January

Prognostication in ET: old and new

Time to revisit prognostication in PV?

FEBRUARY

Masked PV: what is it?

Fedratinib for MF in 2022

MARCH

Pacritinib for MF patients with low platelets

Management of anemia in MF

APRIL

Update on CNL/aCML

MPN-unclassifiable and MPN/MDS-unclassifiable

MAY

Approach to eosinophilia

COVID and MPN

JUNE

Pediatric/AYA MPN

Standard and novel therapies for ET

JULY

Prefibrotic myelofibrosis: diagnosis and management

Should interferon be standard first line therapy for high risk PV patients?

AUGUST

When to use ruxolitinib in the management of PV

Prognostication for MF: which prognostic scoring system?

SEPTEMBER

When to start therapy for MF with a JAK2 inhibitor: goals of therapy

Upcoming non-JAKi drugs and combinations for MF

OCTOBER

Management of side effects in MF patients on JAK2 inhibitors

Suboptimal response/loss of response to ruxolitinib for MF

NOVEMBER

Optimal use of transplant in MF

Accelerated phase MPN: what is it and how to manage it?

DECEMBER

Update on systemic mastocytosis

Quality of life in MF: JAK2i and HSCT

FACULTY REVIEW

FACULTY GROUP REVIEW AT THE END OF THE 12 MONTHS TO REFLECT ON KEY DEVELOPMENTS

If you would like additional information or have any questions, please email:

office@md-education.com

ORGANISED BY:

UK Office

MD Education Ltd
4/4a Bloomsbury Square, London , WC1A 2RP

USA Office

MD Education USA LLC,
4600 140th Avenue North, Suite 180, Clearwater, Florida 33762

Privacy Policy | Cookie Policy

Developed by Unet

Ruben Mesa, MD, FACP recently began his tenure leading the mission and programs against cancer across Atrium Health and Atrium Health Wake Forest Baptist with the joint roles of President, Enterprise Cancer Service Line Atrium Health; Enterprise Senior Vice President for Atrium Health; Executive Director of the NCI Comprehensive Cancer based at Wake Forest Baptist; and Vice Dean for cancer programs at Wake Forest School of Medicine. In these roles Dr. Mesa oversees all efforts related to cancer practice, research and education across Atrium Health as a system including Wake Forest Baptist, Levine Cancer Institute, and all regional sites. Dr. Mesa previously was the Executive Director of the NCI Designated Mays Cancer Center at UT Health San Antonio MD Anderson from 2017-2023 where he developed and grew the cancer service line, co-led the development and construction of a new cancer focused hospital, grew cancer faculty, peer reviewed funded research and successful renewed the NCI designation in 2020. Earlier in his career Dr Mesa practiced hematology at Mayo Clinic (MN 2002-2009, and Arizona (2009-2017)) where he was Chair of Hematology & Medical Oncology and Deputy Director of the Mayo Clinic Comprehensive Cancer Center.

Dr Mesa, is an international expert in hematologic cancers, who has dedicated his life’s work to research and drug development for myeloproliferative neoplasms (MPNs), a group of chronic leukemias that can cause difficult symptoms, bone marrow problems, acute leukemia and premature death. He has been involved in MPN research for more than 20 years. Dr. Mesa’s research focuses on MPN biology, novel therapeutics and over 100 phase I-III clinical trials, symptom assessment tools (led the development of the globally utilized MPN Symptom Assessment Form and Myelofibrosis Symptom Assessment Form) and non-pharmacological interventions to alleviate MPN symptoms. He has over 800-lifetime medical publications, with more than 400 peer-reviewed manuscripts, 15 book chapters and two edited books. He is a frequently invited speaker on MPNs with over 600 such lectures and visiting professorships, nationally and internationally. Dr. Mesa has led or co-led the development of six drugs that have been FDA approved for myeloproliferative neoplasms including ruxolitinib (myelofibrosis 2011 and polycythemia vera in 2014), fedratinib (myelofibrosis 2019), ropegylated interferon a2b (PV 2021), avapritinib (systemic mastocytosis 2021), pacritinib (myelofibrosis 2022) and momelotinib pending approval (anticipated 2023). Dr. Mesa was the inaugural panel chair of the National Comprehensive Cancer Network’s (NCCN) guideline panel for the first USA guidelines for MPNS (myelofibrosis, polycythemia vera and essential thrombocythemia).

Dr. Mesa is a funded investigator of the National Cancer Institute (NCI) on several projects in myeloproliferative neoplasms and has been appointed to the NCI Clinical Trial Advisory Committee. He plays a range of leadership roles with the American Society of Hematology (ASH), the American Association of Cancer Research (AACR), and is currently elected to the Board of the American Association of Cancer Institutes (AACI) and an executive officer of the board for the Leukemia and Lymphoma Society. Dr. Mesa has won many career awards for his research from Mayo Clinic, from patient and MPN organizations.

In addition to Dr. Mesa’s extensive MPN research and clinical practice, he is passionate about advancing cancer health equity and increasing minority patients’ participation in cancer clinical trials. He helped implement a mandate that each new trial at the Mays Cancer Center had a Minority Accrual Plan. He is involved in numerous national initiatives to increase clinical trial diversity, including being a member of the Genentech Health Disparities Task Force, Bristol Myers Squibb Health Disparities Task Force and the Janssen Health Disparities Task Force. In March 2022, he testified on the importance of clinical trial diversity before the House Committee on Energy and Commerce. Dr. Mesa also co-led the Mays Cancer Center’s biennial Advancing the Science of Cancer in Latinos Conference held in San Antonio.

Tiziano Barbui was graduated at the University of Padua (Italy). He was Consultant in
Hematology at San Bortolo Hospital in Vicenza and founded the Department of Hematology at
“Ospedali Riuniti di Bergamo” where he was the Director from 1981 to 2008 and chief of
department of Oncology and Hematology. He was an adjunct professor in the school of
specialization in hematology of the Universities of Milan (State and Bicocca University) and Verona University.
Professor Barbui is currently the Scientific Director of FROM Research Foundation at Papa Giovanni XXIII Hospital, Bergamo (Italy).
He has served as Chairman on the Subcommittee on Lupus Anticoagulant of the International
Society of Thrombosis and Haemostasis, and was former President of the Italian Society of Hematology.
Currently, he leads the European-Leukemia-Net WP-9 on Myeloproliferative Disorders. He is one
of the founders of the NIH (US) Myeloproliferative Disorders Consortium. Currently he is a
member og the Good Governance Committee of European Hematology Association (EHA).
Professor Tiziano Barbui published so far more than 700 scientific articles in International peer
reviewed journals and is among the top 50 Italian scientists according to the Virtual Italian
Academy. During decades he significantly contributed to many fields of general hematology. The
most cited articles refer to the Lupus anticoagulant syndrome, the hemostatic disturbances and
therapy of acute leukemia, the optimization of diagnosis, prognosis and treatment of
myeloproliferative neoplasms.he is one the principal promoters of European LeukemiaNet guidelines on MPN
He has been the principal investigator in several academic clinical trials published in the New England Journal of Medicine.

Prof. Barbui received the gold medal from the Bergamo City Hall for his continued dedication for
the care of patients with malignant hematologic diseases and for his contribution to the advance of
hematology science. During the European Hematology Association (EHA) meeting in Stockholm
(2013), he received the “Jean Bernard award” for his contribution to optimization of diagnosis,
prognosis and therapy of the Myeloproliferative neoplasms and for establishing international
networks for clinical research in Hematology.
He is currently very involved in research of COVID on behalf of European Leukemia Net (ELN)
and Europen Hematology Association (EHA) and in clinical trials of MPN.